

Albert Farrugia

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7566188/albert-farrugia-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

147
papers

1,607
citations

20
h-index

34
g-index

163
ext. papers

1,823
ext. citations

4.2
avg, IF

5.17
L-index

#	Paper	IF	Citations
147	Fresh frozen plasma: Beyond coagulation factor content.. <i>Transfusion Medicine</i> , 2022 ,	1.3	
146	Urgent Need to Regulate Convalescent Plasma Differently from Thawed Plasma. <i>Transfusion Medicine and Hemotherapy</i> , 2021 , 48, 132-133	4.2	1
145	Estimation of the latent therapeutic demand for immunoglobulin therapies in autoimmune neuropathies in the United States. <i>Vox Sanguinis</i> , 2021 ,	3.1	1
144	ABO-incompatible convalescent plasma transfusion: Yes, you can. <i>Transfusion Medicine</i> , 2021 , 31, 215-216	3	2
143	The interphase between immunoglobulin, the plasma industry and the public health, managing a finite resource. <i>Transfusion Clinique Et Biologique</i> , 2021 , 28, 86-88	1.9	
142	The art of the possible in approaching efficacy trials for COVID19 convalescent plasma. <i>International Journal of Infectious Diseases</i> , 2021 , 102, 244-246	10.5	6
141	Appropriately specifying the quality of plasma for fractionation. <i>Vox Sanguinis</i> , 2021 ,	3.1	
140	The safety of plasma-derived haemophilia factor concentrates - comments on "Deep viral metagenomics in patients with haemophilia receiving plasma-derived coagulation factor concentrates" Nunes Valenã I et' al. (2021). Deep viral metagenomics in patients with haemophilia receiving plasma-derived coagulation factor concentrates. <i>Haemophilia</i> .	3.3	
139	The discovery of cryoprecipitate as a modality for hemophilia A: Augmenting the allocation of credit. <i>Transfusion</i> , 2021 , 61, 2517-2518	2.9	0
138	Storage of cryoprecipitate: Role of blood storage. <i>Transfusion</i> , 2021 , 61, 2800-2801	2.9	0
137	Albumin in plasma exchange - A rethink is required. <i>Transfusion and Apheresis Science</i> , 2021 , 60, 103175	2.4	
136	Convalescent plasma - this is no time for competition. <i>Transfusion</i> , 2020 , 60, 1644-1646	2.9	4
135	Plasma from donors convalescent from SARS-CoV-2 infection-A matter of priorities. <i>Transfusion Clinique Et Biologique</i> , 2020 , 27, 167-168	1.9	3
134	The impact of the SARS-CoV-2 outbreak on the safety and availability of blood transfusions in Italy. <i>Vox Sanguinis</i> , 2020 , 115, 603-605	3.1	37
133	Concerns regarding immunoglobulins. <i>Transfusion and Apheresis Science</i> , 2020 , 59, 102693	2.4	
132	Supporting Garraud' and protecting transfusion. <i>Transfusion Clinique Et Biologique</i> , 2020 , 27, 170-171	1.9	1
131	Health-Related Quality of Life in Patients with CVID Under Different Schedules of Immunoglobulin Administration: Prospective Multicenter Study. <i>Journal of Clinical Immunology</i> , 2019 , 39, 159-170	5.7	9

130	Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia. <i>Expert Review of Hematology</i> , 2019 , 12, 883-892	2.8	1
129	Comparing objective and self-reported measures of adherence in haemophilia. <i>Haemophilia</i> , 2019 , 25, 821-830	3.3	12
128	Pharmacokinetics of a new human plasma-derived double virus inactivated and nanofiltered factor IX concentrate in previously treated severe or moderately severe haemophilia B patients. <i>Haemophilia</i> , 2019 , 25, e364-e367	3.3	2
127	Reply to "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis" by Messori et al. <i>Blood Transfusion</i> , 2019 , 17, 85	3.6	1
126	Cost of pathogen reduction for platelets: reply to Cicchetti et al. <i>Blood Transfus</i> 2018; 16: 483-9. <i>Blood Transfusion</i> , 2019 , 17, 84	3.6	
125	The growing importance of achieving national self-sufficiency in immunoglobulin in Italy. The emergence of a national imperative. <i>Blood Transfusion</i> , 2019 , 17, 449-458	3.6	4
124	Comparative analysis of marketed factor VIII products: comment. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 232-233	15.4	1
123	Herd immunity and primary immune deficiencies. <i>Vaccine</i> , 2019 , 37, 3942-3943	4.1	3
122	The multiple benefits of sport in haemophilia. <i>Haemophilia</i> , 2018 , 24, 341-343	3.3	1
121	Perspectives on haemophilia access in Brazil?. <i>Haemophilia</i> , 2018 , 24, e255-e256	3.3	2
120	Factors affecting the quality, safety and marketing approval of clotting factor concentrates for haemophilia. <i>Blood Transfusion</i> , 2018 , 16, 525-534	3.6	3
119	Factor VIII manufactured from plasma—the ups and downs, and the up again: a personal journey—part 1: history of the development of plasma-derived factor VIII therapies. <i>Annals of Blood</i> , 2018 , 3, 17-17	0.6	
118	Factor VIII manufactured from plasma—the ups and downs, and the up again: a personal journey—part 2: aspects of factor VIII manufacture from plasma. <i>Annals of Blood</i> , 2018 , 3, 20-20	0.6	
117	Improving access to haemophilia therapies—Beyond humanitarian aid. <i>Haemophilia</i> , 2018 , 24, e430-e432	3.3	1
116	The dynamics of contract plasma fractionation. <i>Biologicals</i> , 2017 , 46, 159-167	1.8	9
115	Time to review the way we estimate access to haemophilia concentrates worldwide. <i>Haemophilia</i> , 2017 , 23, e235-e237	3.3	
114	Usual and unusual mutations in a cohort of Belgian patients with hemophilia B. <i>Thrombosis Research</i> , 2017 , 149, 25-28	8.2	1
113	Innovation in Hemophilia Therapies - "And Miles to Go, before [We] Sleep". <i>Seminars in Thrombosis and Hemostasis</i> , 2017 , 43, 105-106	5.3	

112	Concerns regarding clinical trials in haemophilia-Augmenting Iorio "Research and policy implications of a recently published controlled study in previously untreated haemophilia patients at high risk of inhibitor development" <i>Haemophilia</i> (2017), 1-3 https://doi.org/10.1111/hae.13176 . <i>Haemophilia</i> , 2017 , <i>23</i> , e475-e476	3.3	
111	Reply to Flanagan "The Code of Ethics of the International Society of Blood Transfusion" [Blood Transfus 2015; 13: 537-8]. <i>Blood Transfusion</i> , 2017 , <i>15</i> , 286-288	3.6	4
110	Are we optimising outcomes in Australia? framework for the supply of plasma-derived medicines?. <i>Medical Journal of Australia</i> , 2016 , <i>205</i> , 336	4	3
109	Safety Issues of Plasma-Derived Products for Treatment of Inherited Bleeding Disorders. <i>Seminars in Thrombosis and Hemostasis</i> , 2016 , <i>42</i> , 583-8	5.3	10
108	Where now for transfusion: the evolution of a paradigm and its logical progression. <i>Transfusion</i> , 2016 , <i>56</i> Suppl 2, S224-32	2.9	2
107	The Ethics of Paid Plasma Donation: A Plea for Patient Centeredness. <i>HEC Forum</i> , 2015 , <i>27</i> , 417-29	1.1	9
106	Assessing options for treating haemophilia with inhibitors. <i>Haemophilia</i> , 2015 , <i>21</i> , 307-9	3.3	3
105	Hemolysis in patients with antibody deficiencies on immunoglobulin replacement treatment. <i>Transfusion</i> , 2015 , <i>55</i> , 1067-74	2.9	19
104	Estimation of the latent therapeutic demand for albumin in the USA: a focus on three indications. <i>Critical Care</i> , 2015 , <i>19</i> , P354	10.8	78
103	Reflections on the emergence of chikungunya virus in the United States: time to revisit a successful paradigm for the safety of blood-derived therapies. <i>Transfusion</i> , 2015 , <i>55</i> , 224-6	2.9	4
102	Issues in assessing products for the treatment of hemophilia - the intersection between efficacy, economics, and ethics. <i>Journal of Blood Medicine</i> , 2015 , <i>6</i> , 185-95	2.3	5
101	Errors and Omissions: Donor Compensation Policies and Richard Titmuss. <i>HEC Forum</i> , 2015 , <i>27</i> , 319-30	1.1	2
100	Some reflections on the Code of Ethics of the International Society of Blood Transfusion. <i>Blood Transfusion</i> , 2015 , <i>13</i> , 551-8	3.6	12
99	Modeling primary immunodeficiency disease epidemiology and its treatment to estimate latent therapeutic demand for immunoglobulin. <i>Journal of Clinical Immunology</i> , 2014 , <i>34</i> , 233-44	5.7	32
98	Albumin: Therapeutic Role in the Current Era 2014 , 395-404		
97	Choice of Fluids in Severe Septic Patients - A Cost-effectiveness Analysis Informed by Recent Clinical Trials. <i>Reviews on Recent Clinical Trials</i> , 2014 , <i>9</i> , 21-30	1.2	12
96	Products Used to Treat Hemophilia: Regulation 2014 , 185-191		
95	Manufacture of immunoglobulin products for patients with primary antibody deficiencies - the effect of processing conditions on product safety and efficacy. <i>Frontiers in Immunology</i> , 2014 , <i>5</i> , 665	8.4	17

94	Hemophilia treatment and the AIDS tragedy: closing the circle. <i>Transfusion</i> , 2014 , 54, 1199	2.9	
93	Joint WFH-ISTH session: issues in clinical trial design. <i>Haemophilia</i> , 2014 , 20 Suppl 4, 137-44	3.3	6
92	Toward a patient-based paradigm for blood transfusion. <i>Journal of Blood Medicine</i> , 2014 , 5, 5-13	2.3	6
91	Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment. <i>Haemophilia</i> , 2013 , 19, e228-38	3.3	40
90	Economic considerations on transfusion medicine and patient blood management. <i>Baillieres Best Practice and Research in Clinical Anaesthesiology</i> , 2013 , 27, 59-68	4	52
89	Relative survival benefit and morbidity with fluids in severe sepsis - a network meta-analysis of alternative therapies. <i>Current Drug Safety</i> , 2013 , 8, 236-45	1.4	17
88	Is self-sufficiency in haemotherapies a practical or necessary goal?. <i>Blood Transfusion</i> , 2013 , 11, 183-92	3.6	11
87	Assessing causality in the transmission of viruses by blood products. <i>Transfusion</i> , 2012 , 52, 1598; author reply 1598-9	2.9	0
86	Letter to the editor--Response to How expanding voluntary non-remunerated blood donations would benefit patients, donors and healthcare systems? F. Rossi, R. Perry, J. de Wit, T. Evers & G. Follá, <i>Vox Sanguinis</i> DOI: 10.1111/j.1423-0410.2011.01495.x. <i>Vox Sanguinis</i> , 2012 , 102, 269-70	3.1	1
85	Albumin from rice: why and wherefore?. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, E775	11.5	
84	Health technology assessment and haemophilia. <i>Haemophilia</i> , 2012 , 18, 152-7	3.3	17
83	External financial aid to blood transfusion services in sub-Saharan Africa: a need for reflection. <i>PLoS Medicine</i> , 2012 , 9, e1001309	11.6	56
82	The Boldt affair: correcting a collective failure. <i>Anesthesia and Analgesia</i> , 2012 , 115, 207	3.9	7
81	Plasma-derived medicines: access and usage issues. <i>Blood Transfusion</i> , 2012 , 10, 273-8	3.6	12
80	HIV safety in sub-Saharan Africa. <i>Vox Sanguinis</i> , 2011 , 100, 434-5; author reply 436-7	3.1	3
79	Response to Laub et al., Specific protein content of pools of plasma for fractionation from different sources: impact of frequency of donations Vox Sanguinis (2010) 99, 220-231. <i>Vox Sanguinis</i> , 2011 , 100, 438; author reply 439	3.1	1
78	A study of reported factor IX use around the world. <i>Haemophilia</i> , 2011 , 17, 446-55	3.3	19
77	Falsification or paradigm shift? Toward a revision of the common sense of transfusion. <i>Transfusion</i> , 2011 , 51, 216-24	2.9	13

76	Conditions for plasma processing. <i>Transfusion</i> , 2011 , 51, 1875-6; author reply 1876	2.9	
75	Safety of plasma volume expanders. <i>Journal of Clinical Pharmacology</i> , 2011 , 51, 292-300	2.9	12
74	A study of reported factor VIII use around the world. <i>Haemophilia</i> , 2010 , 16, 33-46	3.3	66
73	Payment, compensation and replacement--the ethics and motivation of blood and plasma donation. <i>Vox Sanguinis</i> , 2010 , 99, 202-11	3.1	68
72	Concerning Chapter 5 - Human Albumin; in Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives, 4th ed. <i>Transfus Med Hemother</i> 2009;36(6):399-407. <i>Transfusion Medicine and Hemotherapy</i> , 2010 , 37, 98-99	4.2	4
71	Products used to Treat Hemophilia: Regulation 2010 , 170-175		
70	Albumin usage in clinical medicine: tradition or therapeutic?. <i>Transfusion Medicine Reviews</i> , 2010 , 24, 53-63	7.4	126
69	Response to Volkow P et al. - Cross-border paid plasma donation among injection drug users in two Mexico-U.S. border cities - <i>International Journal of Drug Policy</i> 20 (2009) 409-412. <i>International Journal of Drug Policy</i> , 2010 , 21, 343-4; discussion 345-6	5.5	1
68	Trialing plasma protein therapies for rare disorders: Thinking outside the box. <i>Pharmaceuticals Policy and Law</i> , 2009 , 11, 345-352		1
67	Stem cell and cellular therapy developments. <i>Biologicals</i> , 2009 , 37, 103-7	1.8	10
66	Plasma fractionation issues. <i>Biologicals</i> , 2009 , 37, 88-93	1.8	31
65	Remuneration of blood donors: let us compare apples with apples. <i>Vox Sanguinis</i> , 2009 , 96, 349; author reply 350-1	3.1	1
64	Globalisation and blood safety. <i>Blood Reviews</i> , 2009 , 23, 123-8	11.1	15
63	A Regulatory System for Cell and Tissue Therapies: Proposed Approach in Australia 2009 , 37-48		
62	Trends in prevalence of viral infections in Australian musculoskeletal tissue donors and projections of incidence and residual risk, 1993-2004. <i>Transplantation</i> , 2008 , 86, 746-8	1.8	
61	Comparison of the risk of viral infection between the living and nonliving musculoskeletal tissue donors in Australia. <i>Transplant International</i> , 2008 , 21, 936-41	3	7
60	Regulatory oversight of cellular therapies. <i>ISBT Science Series</i> , 2007 , 2, 141-146	1.1	1
59	Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004. <i>Transfusion</i> , 2007 , 47, 529-39	2.9	60

58	The risk of HIV, HBV, HCV and HTLV infection among musculoskeletal tissue donors in Australia. <i>American Journal of Transplantation</i> , 2007 , 7, 2723-6	8.7	55
57	Theoretically estimated risk of severe acute respiratory syndrome transmission through blood transfusion during an epidemic in Shenzhen, Guangdong, China in 2003. <i>Transfusion and Apheresis Science</i> , 2007 , 37, 233-40	2.4	11
56	Iron and blood donation- an under-recognised safety issue. <i>Developments in Biologicals</i> , 2007 , 127, 137-46		5
55	Assessing efficacy and therapeutic claims in emerging indications for recombinant factor VIIa: regulatory perspectives. <i>Seminars in Hematology</i> , 2006 , 43, S64-9	4	1
54	Plasma protein therapies: current and future perspectives. <i>Best Practice and Research in Clinical Haematology</i> , 2006 , 19, 243-58	4.2	28
53	Global Forum of the World Federation of Hemophilia, September 26-27, 2005, Montreal, Quebec, Canada. <i>Transfusion and Apheresis Science</i> , 2006 , 35, 151-172	2.4	1
52	Challenges in the evaluation of safety and efficacy of human tissue and cell based products. <i>ANZ Journal of Surgery</i> , 2006 , 76, 843-9	1	4
51	Globalization and blood safety. <i>ISBT Science Series</i> , 2006 , 1, 25-32	1.1	1
50	When do tissues and cells become products? Regulatory oversight of emerging biological therapies. <i>Cell and Tissue Banking</i> , 2006 , 7, 325-35	2.2	17
49	Variant Creutzfeldt-Jakob disease transmission by plasma products: assessing and communicating risk in an era of scientific uncertainty. <i>Vox Sanguinis</i> , 2005 , 89, 186-92	3.1	19
48	Safety and supply of haemophilia products: worldwide perspectives. <i>Haemophilia</i> , 2004 , 10, 327-33	3.3	16
47	Plasma for fractionation: safety and quality issues. <i>Haemophilia</i> , 2004 , 10, 334-40	3.3	34
46	Emerging and receding risks of therapeutic regimens for haemophilia. <i>Haemophilia</i> , 2004 , 10 Suppl 4, 47-54	3.3	7
45	Product delivery in the developing world: options, opportunities and threats. <i>Haemophilia</i> , 2004 , 10 Suppl 4, 77-82	3.3	7
44	Regulatory challenges to global harmonization and expanded access to concentrates: how will regulators balance the increasing cost of new safety requirements with the desire to increase the availability of affordable product?. <i>Haemophilia</i> , 2004 , 10 Suppl 4, 83-7	3.3	
43	Choice of replacement therapy for hemophilia-cryoprecipitate issues: a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2004 , 2, 1022-3	15.4	8
42	The mantra of blood safety: time for a new tune?. <i>Vox Sanguinis</i> , 2004 , 86, 1-7	3.1	22
41	Potency assessment of the new generation of coagulation factor concentrates ¶time for a new paradigm?. <i>Thrombosis and Haemostasis</i> , 2003 , 90, 968-970	7	6

40	Risk of parvovirus infection by immunoglobulin. <i>British Journal of Haematology</i> , 2003 , 121, 955-6; author reply 956	4.5	3
39	The regulatory pendulum in transfusion medicine. <i>Transfusion Medicine Reviews</i> , 2002 , 16, 273-82	7.4	19
38	Evolving perspectives in product safety for haemophilia. <i>Haemophilia</i> , 2002 , 8, 236-43	3.3	22
37	Haemophilia 2002: emerging risks of treatment. <i>Haemophilia</i> , 2002 , 8, 221-9	3.3	18
36	Risk of variant Creutzfeldt-Jakob disease from factor concentrates: current perspectives. <i>Haemophilia</i> , 2002 , 8, 230-5	3.3	21
35	Laboratory practice and studies of bovine spongiform encephalopathy. <i>Lancet, The</i> , 2002 , 359, 1067-8	4.0	2
34	Intravenous immunoglobulin: regulatory perspectives on use and supply. <i>Transfusion Medicine</i> , 2001 , 11, 63-74	1.3	30
33	Flow-cytometric method for the quantitation of the Fc function of intravenous immunoglobulin preparations. <i>Vox Sanguinis</i> , 2000 , 78, 185-93	3.1	1
32	Biological activity of von Willebrand factor during the manufacture of therapeutic factor VIII concentrates as determined by the collagen-binding assay. <i>Biologicals</i> , 1998 , 26, 155-66	1.8	13
31	Measurement of anticomplementary activity in therapeutic intravenous immunoglobulin preparations. <i>Biologicals</i> , 1997 , 25, 87-92	1.8	13
30	Potency measurement of factor VIII in recombinant concentrates. <i>Haemophilia</i> , 1996 , 2, 153-9	3.3	2
29	Platelet size analysis in the quality assurance of platelet concentrates for transfusion. <i>International Journal of Laboratory Hematology</i> , 1995 , 17, 51-5		9
28	Hepatitis C virus transmission by intravenous immunoglobulin. <i>Lancet, The</i> , 1995 , 346, 373-375	4.0	4
27	Platelet concentrates for transfusion-metabolic and storage aspects. <i>Platelets</i> , 1994 , 5, 177-85	3.6	7
26	Relative efficiency of leucocyte removal procedures for the production of leucocyte-poor red cell concentrates assessed by flow cytometry. <i>Vox Sanguinis</i> , 1994 , 66, 153-60	3.1	11
25	In vitro properties of additive suspended red cells collected into a dextrose-free anticoagulant. <i>Transfusion Science</i> , 1994 , 15, 73-78		
24	Components prepared from blood collected into dextrose-free anticoagulant. In vitro properties of platelets suspended in plasma and in dextrose-free synthetic medium. <i>Transfusion Science</i> , 1993 , 14, 409-416		2
23	Cryopreservation of red blood cells: effect of freezing on red cell quality and residual lymphocyte immunogenicity. <i>Journal of Clinical Pathology</i> , 1993 , 46, 742-5	3.9	6

22	Stabilization of von Willebrand factor in banked blood by leucocyte depletion. <i>Transfusion Medicine</i> , 1993 , 3, 51-7	1.3	12
21	Storage of platelet concentrates harvested from blood collected into dextrose-free preservative without agitation. <i>Transfusion Medicine</i> , 1993 , 3, 223-228	1.3	2
20	Biotechnology and the plasma fractionation industry--the impact of advances in the production of coagulation factor VIII. <i>Australasian Biotechnology</i> , 1993 , 3, 16-20		
19	Modulation of fibrinogen content in cryoprecipitate by temperature manipulation during plasma processing. <i>Transfusion</i> , 1992 , 32, 755-9	2.9	7
18	Factor VIII/von Willebrand factor levels in plasma frozen to -30 degrees C in air or halogenated hydrocarbons. <i>Thrombosis Research</i> , 1992 , 68, 97-102	8.2	6
17	von Willebrand factor characterization of a severe dry-heat treated factor VIII concentrate, AHF (high purity). <i>Thrombosis Research</i> , 1992 , 65, 389-99	8.2	7
16	Red Cell and Platelet Concentrates from Blood Collected into Half- Strength Citrate Anticoagulant: Improved Maintenance of Red Cell 2,3-Diphosphoglycerate in Half-Citrate Red Cells. <i>Vox Sanguinis</i> , 1992 , 63, 31-38	3.1	
15	Red cell and platelet concentrates from blood collected into half-strength citrate anticoagulant: improved maintenance of red cell 2,3-diphosphoglycerate in half-citrate red cells. <i>Vox Sanguinis</i> , 1992 , 63, 31-8	3.1	21
14	Some characteristics of blood shed into the Solcotrans postoperative orthopaedic drainage/reinfusion system. <i>Medical Journal of Australia</i> , 1992 , 157, 95-6	4	1
13	Improved in-vitro quality of platelet concentrates stored in a dextrose-free synthetic medium. <i>Transfusion Medicine</i> , 1991 , 1, 31-8	1.3	11
12	Viral safety of coagulation factor concentrates. <i>Transfusion Science</i> , 1991 , 12, 161-162		
11	Use of plasma with high levels of ionised calcium in the production of model scale coagulation factor concentrates. <i>Thrombosis and Haemostasis</i> , 1990 , 64, 374-8	7	1
10	Use of Plasma with High Levels of Ionised Calcium in the Production of Model Scale Coagulation Factor Concentrates. <i>Thrombosis and Haemostasis</i> , 1990 , 64, 374-378	7	8
9	Microtitre plate measurement of platelet response to hypotonic stress. <i>Journal of Clinical Pathology</i> , 1989 , 42, 1298-301	3.9	7
8	Effects of plasma collection systems and processing parameters on the quality of factor IX concentrate. <i>Vox Sanguinis</i> , 1989 , 57, 4-9	3.1	7
7	A microtitre plate test for assessment of in-vitro thrombogenicity in factor IX concentrates using a chromogenic substrate. <i>Thrombosis Research</i> , 1989 , 53, 191-6	8.2	
6	Studies on the Procurement of Blood Coagulation Factor VIII in vitro Studies on Blood Components Prepared in Half-Strength Citrate Anticoagulant. <i>Vox Sanguinis</i> , 1987 , 52, 257-264	3.1	2
5	Studies on the procurement of blood coagulation factor VIII in vitro studies on blood components prepared in half-strength citrate anticoagulant. <i>Vox Sanguinis</i> , 1987 , 52, 257-64	3.1	61

4	Studies on the procurement of blood coagulation factor VIII: effects of plasma freezing rate and storage conditions on cryoprecipitate quality. <i>Journal of Clinical Pathology</i> , 1985 , 38, 433-7	3.9	11
3	Donation procedure, fibrinopeptide A, and factor VIII. <i>Vox Sanguinis</i> , 1984 , 46, 55-7	3.1	17
2	A comparative study using immunological and biological assay of the haemostatic responses to DDAVP infusion venous occlusion and exercise in normal men. <i>Thrombosis and Haemostasis</i> , 1984 , 51, 110-4	7	6
1	Studies on the Procurement of Coagulation Factor VIII: Selective Precipitation of Factor VIII with Hydrophilic Polymers. <i>Thrombosis and Haemostasis</i> , 1984 , 51, 338-342	7	5